EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 531 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Time to get stratified January 10, 2023 FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid... November 26, 2024 Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer April 7, 2026 New option to treat advanced oesophageal cancer approved for NHS in... August 11, 2021 Load more HOT NEWS High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults... Breakthrough SARS-CoV-2 Infection Following COVID-19 Vaccination in Patients with Cancer Dual Inhibition of LAG-3 and PD-1 in Patients with Previously Untreated... Intercontinental Asian Study Compiles the Relative Incidence of non-Hodgkin T-cell Lymphoma...
